Midland Pharmaceuticals
Clinical-stage therapeutics for spinal cord injury and ischemic stroke patients
Highlights
- Young companyFounded 2024
- New on EvolcAdded 2026-11-01
About Midland Pharmaceuticals
Midland Pharmaceuticals is developing MLP-1236, a therapeutic candidate for spinal cord injury and ischemic stroke.
The company is clinical stage. It says a Phase 2b proof-of-concept trial in spinal cord injury patients is planned after completion of ongoing financing.
Midland Pharmaceuticals Ltd was founded in 2024 and is headquartered in London. It was co-founded by NLC Ventures, CEO Peter D. Suzdak, and professors Zubair Ahmed and Arshad Majid.
Product: MLP-1236, a therapeutic candidate for spinal cord injury and ischemic stroke.
Jobs at Midland Pharmaceuticals
No open positions listed right now.
More biotech & pharma companies
Mission Therapeutics
Develops small-molecule deubiquitylating enzyme (DUB) inhibitors for Parkinson's and other serious diseases, alone and with pharma partnersNew on EvolcMoolec Science
Produces animal proteins and plant-based ingredients in crops such as soybean and safflower for food companies worldwideNew on EvolcMyricx Pharma
Develops antibody-drug conjugate cancer therapies using payloads based on N-myristoyltransferase inhibitorsNew on EvolcNeurolieve Biosciences
Developing a non-opioid biologic for patients with neuropathic pain, designed to relieve pain and support nerve regenerationYoung companyNew on EvolcNexus Bioquest
Immunology CRO running custom assays and pre-clinical drug discovery studies for pharma and biotech teamsYoung companyNew on EvolcNonacus
Liquid biopsy NGS panels and kits for cancer detection and monitoring, sold to clinical labs, hospitals and researchersNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Apache
- Elementor
- WordPress
- jQuery